CH0499880968
© PR Newswire
08.01.2026
ADCT
LISTED
NYSE
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
News Preview
Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provide expected cash runway at least to 2028Anticipated near-term catalysts include LOTIS-7 complete enrollment in first half of 2026 and LOTIS-5 Phase 3...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
ADCT
LISTED
NYSE
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2026
ADCT
LISTED
NYSE
ADC Therapeutics Announces New Employee Inducement Grant
News Preview
LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company's common shares to a new employee on January 2, 2026 ("Gran...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
19.12.2025
ADCT
LISTED
NYSE
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 19, 2025 /CNW/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from validated mechanisms[1]. Antibody-drug conjugate pipelines expanding p...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
19.12.2025
ADCT
LISTED
NYSE
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
News Preview
Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from validated mechanisms[1]. Antibody-drug conjugate pipelines expa...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
News Preview
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-upCombination continues to be generally well-tolerated with a manageable safety profileLOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full dat...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
News Preview
Company to host corporate webcast to share updated data on December 3, 2025LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3,...
Themefolio
Profiler
Peergroup
© PR Newswire
01.12.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Dec. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 47,000 of the Company's common shares to two new employees on December 1, 2025 (e...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ADCT
LISTED
NYSE
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
News Preview
Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026
Updated data from Phase 2 IIT of ZYNLONTA®
plus rituximab in patients with r/r follicular lymphoma presented at the 22nd...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
News Preview
LAUSANNE, Switzerland, Nov. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, November 10, 2025, at 8:30 a.m. EST to report financia...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Present at November Investor Conferences
News Preview
LAUSANNE, Switzerland, Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November:...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces $60 Million Private Placement
News Preview
LAUSANNE, Switzerland, Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutiona...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.10.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 162,000 of the Company's common shares to four new employees on October 1, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 29,700 of the Company's common shares to two new employees on September 2, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
News Preview
LAUSANNE, Switzerland, Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
ADCT
LISTED
NYSE
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
News Preview
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients
Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shared in second half of 2025
LOTIS-5 Phase 3 trial expected...
Themefolio
Profiler
Peergroup
© PR Newswire
05.08.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
News Preview
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common shares to three new employees on August 1, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
News Preview
LAUSANNE, Switzerland, July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each,...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
ADCT
LISTED
NYSE
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
News Preview
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Res...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
ADCT
LISTED
NYSE
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
News Preview
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 26, 2025 /CNW/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research R...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
ADCT
LISTED
NYSE
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
News Preview
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Res...
Themefolio
Profiler
Peergroup
© PR Newswire
16.06.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
News Preview
Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69%
CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment
ZYNLONTA was generally well tolerated and safety was consistent with known profile
L...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
News Preview
LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million pr...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
News Preview
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients
25 of 26 patients achieving CR remained in CR as of the data cut-off
Initial data show the combination...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (eac...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Present at Upcoming Investor Conferences
News Preview
LAUSANNE, Switzerland, May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
ADCT
LISTED
NYSE
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
News Preview
LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability
Forty patient enrollment reached in LOTIS-7 trial dose expansion...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
News Preview
ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL
Safety and tolerability data were consistent with the known profiles of each agent
Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
News Preview
LAUSANNE, Switzerland, May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
News Preview
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer
Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs
LAUSANNE, Switzerland, April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT),...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (e...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
News Preview
LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET....
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ADCT
LISTED
NYSE
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
News Preview
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025
Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
ADCT
LISTED
NYSE
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
News Preview
Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models
Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations
LAUSANNE, Switzerland, March 25, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
News Preview
LAUSANNE, Switzerland, March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, March 27, 2025, at 8:30 a.m. EDT to report financial results for the fourth quarter...
Themefolio
Profiler
Peergroup
© PR Newswire
03.02.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Feb. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 26,800 of the Company's common shares to three new employees on February 3, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
30.01.2025
ADCT
LISTED
NYSE
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
News Preview
LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6,...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 20,000 of the Company's common shares to two new employees on January 2, 2025 (e...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
ADCT
LISTED
NYSE
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
News Preview
LAUSANNE, Switzerland, Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituxima...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
ADCT
LISTED
NYSE
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
News Preview
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate
Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients
Company to host conference call tod...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
ADCT
LISTED
NYSE
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
News Preview
Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting
Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95%
Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of 91% and 70% CR
LAUSANNE, Switzerland, De...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
ADCT
LISTED
NYSE
ADC Therapeutics gab auf der 66. Jahrestagung der American Society of Hematology (ASH) bekannt, dass von Forschern initiierte Studienzusammenfassungen zur Präsentation angenommen wurden
News Preview
Mündliche Präsentation der vom Prüfarzt initiierten Phase-2-Studie zur Bewertung von ZYNLONTA® (Loncastuximab-Tesirin-Lpyl) in Kombination mit Rituximab bei Patienten mit r/r follikulärem Lymphom
Posterpräsentation der ersten Zwischenanalyse zur Futility der laufenden, von einem Prüfarzt initiierten klinischen Phase-2-Studie zur Untersuchung von...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
ADCT
LISTED
NYSE
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
News Preview
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma
Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lym...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
ADCT
LISTED
NYSE
ADC Therapeutics präsentiert sich auf Investorenkonferenzen im November
News Preview
LAUSANNE, Schweiz, 4. November 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und innovatives Unternehmen im Bereich der Antikörper-Wirkstoff-Konjugate (Antibody Drug Conjugates, ADCs), gab heute seine Teilnahme an zwei Investorenkonferenzen im November bekannt:
Guggenheim Securities Healthcare Innovation Conferenc...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
ADCT
LISTED
NYSE
ADC Therapeutics to Present at November Investor Conferences
News Preview
LAUSANNE, Switzerland, Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November:...
Themefolio
Profiler
Peergroup
© PR Newswire
02.11.2024
ADCT
LISTED
NYSE
ADC Therapeutics vergibt im Rahmen eines Anreizprogramms Zuschüsse an neue Mitarbeiter
News Preview
LAUSANNE, Schweiz, 2. November 2024 /PRNewswire/ – ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und innovatives Unternehmen im Bereich der Antikörper-Wirkstoff-Konjugate (ADCs), gab heute bekannt, dass das Unternehmen zwei neuen Mitarbeitern am 1. November 2024 Optionen zum Kauf von insgesamt 42.000 Stammaktien des Unternehmens zugesp...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 42,000 of the Company's common shares to two new employees on November 1, 2024 (...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
ADCT
LISTED
NYSE
ADC Therapeutics veranstaltet am 7. November 2024 eine Telefonkonferenz zu den Finanzergebnissen des dritten Quartals 2024
News Preview
LAUSANNE, Schweiz, 31. Oktober 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes Unternehmen und Pionier auf dem Gebiet der Antikörper-Wirkstoff-Konjugate (Antibody Drug Conjugates, ADCs), gab heute bekannt, dass es am Donnerstag, dem 7. November 2024, um 8:30 Uhr EST eine Telefonkonferenz und einen Live-Webcast verans...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
ADCT
LISTED
NYSE
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
News Preview
LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2024
ADCT
LISTED
NYSE
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
News Preview
LAUSANNE, Schweiz, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und innovatives Unternehmen im Bereich der Antikörper-Wirkstoff-Konjugate (AWK), hat heute bekanntgegeben, dass das Unternehmen am 3. September 2024 vier neuen Mitarbeitern Optionen zum Kauf von insgesamt 17.900 Stammaktien des Unternehm...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
ADCT
LISTED
NYSE
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the Company’s common shares to four new employees on September 3...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
ADCT
LISTED
NYSE
ADC Therapeutics to Present at Upcoming Investor Conferences
News Preview
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September:...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
ADCT
LISTED
NYSE
ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt
News Preview
ZYNLONTA® – Nettoumsatz von 17,0 Mio. USD im 2. Quartal 2024; kommerzielle Rentabilität in der ersten Hälfte des Jahres 2024 erreicht...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
ADCT
LISTED
NYSE
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
News Preview
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
ADCT
LISTED
NYSE
ADC Therapeutics veranstaltet am 6. August 2024 eine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2024
News Preview
LAUSANNE, Schweiz, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes, in der Kommerzialisierung tätiges Unternehmen und Pionier auf dem Gebiet der Antikörper-Wirkstoff-Konjugate (AWK), gab heute bekannt, dass es am Dienstag, den 6. August 2024, um 8:30 Uhr EDT eine Telefonkonferenz und einen Live-Webcast a...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
ADCT
LISTED
NYSE
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
News Preview
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial results for the second quarte...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ADCT
LISTED
NYSE
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
News Preview
LAUSANNE, Schweiz, July 02, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen sechs neuen Mitarbeitern am 1. Juli 2024 Zuteilungen für Optionen auf den Erwerb von insgesamt 172.400 Stammaktien des Unternehmens (jeweils eine „Zuteilung“) gewährt hat. Mit den Zuteilungen wurde den Mitarbeitern...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2024
ADCT
LISTED
NYSE
ADC Therapeutics tritt demnächst den Indizes Russell 2000® und Russell 3000® bei
News Preview
LAUSANNE, Schweiz, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen nach Abschluss der jährlichen Neukonstituierung der Russell US-Benchmark-Indizes mit der Eröffnung der US-amerikanischen Aktienmärkte am 1. Juli 2024 dem Russell 2000® Index und dem breiter gefächerten Russell 3000®...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
